168 related articles for article (PubMed ID: 35906470)
1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R; Dorado S; Ruíz-Heredia Y; Martín-Muñoz A; Rosa-Rosa JM; Ribera J; García O; Jimenez-Ubieto A; Carreño-Tarragona G; Linares M; Rufián L; Juárez A; Carrillo J; Espino MJ; Cáceres M; Expósito S; Cuevas B; Vanegas R; Casado LF; Torrent A; Zamora L; Mercadal S; Coll R; Cervera M; Morgades M; Hernández-Rivas JÁ; Bravo P; Serí C; Anguita E; Barragán E; Sargas C; Ferrer-Marín F; Sánchez-Calero J; Sevilla J; Ruíz E; Villalón L; Del Mar Herráez M; Riaza R; Magro E; Steegman JL; Wang C; de Toledo P; García-Gutiérrez V; Ayala R; Ribera JM; Barrio S; Martínez-López J
Sci Rep; 2022 Jul; 12(1):13057. PubMed ID: 35906470
[TBL] [Abstract][Full Text] [Related]
2. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Soverini S; Bavaro L; De Benedittis C; Martelli M; Iurlo A; Orofino N; Sica S; Sorà F; Lunghi F; Ciceri F; Galimberti S; Baratè C; Bonifacio M; Scaffidi L; Castagnetti F; Gugliotta G; Albano F; Russo Rossi AV; Stagno F; di Raimondo F; D'Adda M; di Bona E; Abruzzese E; Binotto G; Sancetta R; Salvucci M; Capodanno I; Girasoli M; Coluzzi S; Attolico I; Musolino C; Calistri E; Annunziata M; Bocchia M; Stella S; Serra A; Errichiello S; Saglio G; Pane F; Vigneri P; Mignone F; Laginestra MA; Pileri SA; Percesepe A; Tenti E; Rosti G; Baccarani M; Cavo M; Martinelli G
Blood; 2020 Feb; 135(8):534-541. PubMed ID: 31877211
[TBL] [Abstract][Full Text] [Related]
7. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
[TBL] [Abstract][Full Text] [Related]
9. Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.
Dey S; Basu S; Shah S; Bhattacharyya D; Gupta PP; Acharjee M; Roychoudhury S; Nath S
Cancer Treat Res Commun; 2022; 33():100635. PubMed ID: 36155130
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
[TBL] [Abstract][Full Text] [Related]
12. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
13. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
[TBL] [Abstract][Full Text] [Related]
14. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
16. Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing.
Abulaiti D; Tuerxun N; Wang H; Abulizi P; Zhao F; Liu Y; Hao J
Cytogenet Genome Res; 2022; 162(4):201-206. PubMed ID: 36167055
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
18. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
20. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
Romzova M; Smitalova D; Tom N; Jurcek T; Culen M; Zackova D; Mayer J; Racil Z
Br J Haematol; 2020 May; 189(3):469-474. PubMed ID: 32037516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
